Anti-angiogenic treatment in the management of metastatic renal cell carcinoma;Les traitements anti-angiogéniques dans la prise en charge du cancer du rein métastatique

Bulletin du Cancer

Volumn 95, Issue 9, 2008, Pages 813-820

  Sire, Marie ^a   Wallerand, Hervé ^b   Kilkoski, Florence ^a   Grenier, Nicolas ^b   Ferrière, Jean Marie ^b   Ravaud, Alain ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

Anti angiogenic treatment; Bevacizumab; Metastatic renal cell carcinoma; Renal cell carcinoma; Sorafenib; Sunitinib

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BEVACIZUMAB; INTERFERON; PLACEBO; SORAFENIB; SUNITINIB;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; ASTHENIA; BLEEDING; BRAIN METASTASIS; CANCER GROWTH; CEREBROVASCULAR ACCIDENT; CHOLESTASIS; CONSTIPATION; CONTROLLED STUDY; CYTOLYTIC HEPATITIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRY SKIN; EPIGASTRIC PAIN; ERYTHEMA; ESOPHAGITIS; FEMALE; GLOSSITIS; HAND FOOT SYNDROME; HEALTH STATUS; HEART FAILURE; HUMAN; HYPOTHYROIDISM; INFECTION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OSTEOARTHROPATHY; OVERALL SURVIVAL; PROGNOSIS; PROTEINURIA; PRURITUS; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES;

EID: 53849134160     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0705     Document Type: Article

References (31)

1. Motzer RJ, Mazumbar M, Bacik J, Berg W, Amsterdam M, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999 ; 17 : 2530-40.
2. Ravaud A, Bay JO. Update on renal cell carcinoma. Bull Cancer 2002 ; 89 : 31-6.
3. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for higt-dose recombinant interleukin-2 in patient with renal cell carcinoma. Cancer J Sci Am 2000 ; 6 : S55-S57.
4. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005 ; 23 : 133-41.
5. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukine-2, recombinant human interferon-alfa-2a or both in metastatic renal-cell carcinoma. Groupe français d'immunothérapie. N Engl J Med 1998 ; 338 : 1272-8.
6. Negrier S. Is intravenous interleukine-2 superior to subcutaneous IL-2 in good prognosis patients with metastatic renal cell carcinoma receiving a combination of IL-2 and alpha interferon? Results of the prospective randomized PERCY DUO trial. Proc Am Soc Clin Oncol J Clin Oncol 2006.
7. Atkins M, Regan M, Mcdermott D, Mier J, Stanbridge E, Youmans A, et al. Carbonic anhydrase IX expression predicts outcome of interleukine-2 therapy for renal cancer. Clin Cancer Res 2005 ; 11 : 3714-21.
8. Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, et al. Medroxyprogesterone, interferon-alpha-2a, interleukin-2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis : results of a randomized controlled trial. Cancer 2007 ; 110 : 2468-77.
9. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002 ; 29 : 15-8.
10. Bay JO, Penault-Llorca F, Ravaud A, Chevreau C, Négrier S, Escudier B. New entities in pathological classification and new therapeutic options in renal cell carcinoma. Bull Cancer 2006 ; 93 : 91-100.
11. Ravaud A. Current options for the treatment of locally advanced and metastatic renal cell carcinoma : focus on sunitinib. Eur J Cancer 2007 ; 5 : 4-11.
12. Billemont B, Méric JB, Izzedine H, Taillade L, Sultan-Amar V, Rixe O. Angiogenesis and renal cell carcinoma. Bull Cancer 2007 ; 94 : S232-S240.
13. Ravaud A, Wallerand H, Culine S, Bernhard JC, Fergelot P, Bensalah K, et al. Update on the medical treatment of locally advanced and metastatic renal cell carcinoma. Eur Urol 2008 ; (sous presse).
14. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006 ; 295 : 2516-24.
15. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 2007 ; 356 : 115-24.
16. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 ; 349 : 427-34.
17. Escudier B, Pluzanska A, Koralewski A, Ravaud A, Bracarda S, Szczylik C, et al., For the AVOREN Trial investigators. Bevacizumab plus interferon-alfa-2a for treatment of metastatic renal cell carcinoma : a randomized, double-blind phase III trial. Lancet 2007 ; 370 : 2103-11.
18. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al., For the TARGET Study Group. Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 2007 ; 356 : 125-34.
19. Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, et al. Randomized phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol J Clin Oncol 2005 ; 23 : 380.
20. Bukowski RM, Eisen T, Szczylik C, Stadler WM, Simantov R, Shan M, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma : survival and biomarker analysis. Proc Am Soc Clin Oncol J Clin Oncol 2007 ; 25 : 5023.
21. Tamaskar I, Bukowski R, Elson P, Iochimescu AG, Wood L, Dreicer R, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 2008 ; 19 : 265-8.
22. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007 ; 99 : 81-3.
23. Izzedine H. Angiogenesis inhibitor therapies : focus on hypertension and kidney toxicity. Bull Cancer 2007 ; 94 : 981-6.
24. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007 ; 18 : 1117.
25. Sablin MP, Bouaita L, Balleyguier C, Gautier J, Celier C, Balcaceres JL, et al. Sequential use of sorafenib and sunitinib in renal cancer : retrospective analysis in 90 patients. Proc Am Soc Clin Oncol J Clin Oncol 2007 ; 25 : 5038.
26. Pouessel D, Culine S. Angiogenesis targeting in renal carcinoma. Bull Cancer 2007 ; 94 : F223-F226.
27. Hudes G, Carducci M, Tomczack P, Dutcher J, Figlin R, Kapoor A, et al., For the Global ARCC Trial. Temsirolimus, interferon-alfa, or both for advanced renal cell carcinoma. N Engl J Med 2007 ; 356 : 2271-81.
28. Ronnen EA, Kondagunta GV, Ishill N, Spodek L, Russo P, Reuter V, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 2006 ; 107 : 2617-21.
29. Diner EK, Linehan M, Walther M. Response of papillary renal cell carcinoma in a solitary kidney to high-dose interleukin therapy. Int J Urol 2005 ; 12 : 996-7.
30. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukine-2 based therapy. J Immunother 2005 ; 28 : 488-95.
31. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008 ; 26 : 127-31.